CoChat

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Open access
Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Singhroy, Diane N, Lie, Yolanda, Petropoulos, Christos J, Huang, Wei, Wainberg, Mark A · 2013 · Retrovirology
Cited by 131

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir. During previous in vitro selection study, we identified a R263K mutation as the most common substitution to arise in the presence of dolutegravir with H51Y arising as a secondary mutation. Additional experiments reported here provide a plausible explanation for the absence of reported dolutegravir resistance among integrase inhibitor-naïve patients to date. Results: We now show that H51Y in combination with R263K increases resistance to dolutegravir but is accompanied by dramatic decreases in both enzymatic activity and viral replication. Conclusions: Since H51Y and R263K may define a unique resistance pathway to dolutegravir, our results are consistent with the absence of resistance mutations in antiretroviral drug-naive patients treated with this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1742-4690-10-22

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 131

Metadata

Authors
Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A.
Venue
Retrovirology
Published
2013-02-22
Volume
10
Issue
1
Pages
22-22
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2110471430
Cited by
131
References
3
FWCI
15.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. https://app.cochat.ai/papers/10.1186/1742-4690-10-22
The paper
Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A. (2013). Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. https://doi.org/10.1186/1742-4690-10-22

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.